# US 2016/0354347 A1 · Nuclear Transport Modulators and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354347 A1
- Document ID: US20160354347A1
- Status: Published application
- Kind: A1
- Application number: 14/989,377
- Filed: 2016-01-06
- Published: 2016-12-08
- Earliest claimed: 2012-05-09
- Assignees: Karyopharm Therapeutics Inc.
- Applicants: Karyopharm Therapeutics Inc.
- Inventors: Vincent P. Sandanayaka; Sharon Shechter; Sharon Shacham; Dilara McCauley; Erkan Baloglu
- Web page: https://patentgrep.com/patent/US20160354347A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

## Claims

### Claim 1

A method for treating a disorder associated with CRM1 activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by structural formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from hydrogen and C1-C4 alkyl;
R2 is selected from O and S; and
R3 is selected from —N(R4)—(C3-C6 cycloalkyl), —C1-C6 alkyl, —(C0-C4 alkylene)-heterocyclyl, and —(C0-C4 alkylene)-heteroaryl, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R3 is optionally and independently substituted; and
R4 is selected from hydrogen and C1-C4 alkyl, and
wherein, the disorder is selected from lupus, multiple sclerosis, amyotrophic lateral sclerosis and rheumatoid arthritis.

### Claim 2 (depends on 1)

The method of claim 1, wherein, R1 is selected from hydrogen and methyl.

### Claim 3 (depends on 2)

The method of claim 2, wherein R1 is hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein R2 is O.

### Claim 5 (depends on 1)

The method of claim 1, wherein R4 is hydrogen.

### Claim 6 (depends on 1)

The method of claim 1, wherein
R3 is selected from —N(R4)—(C3-C6 cycloalkyl), —C3-C6 alkyl, —(C0-C1 alkylene)-heterocyclyl, and —(C0-C1 alkylene)-heteroaryl, wherein:
any alkyl or alkylene portion of R3 is optionally and independently substituted with one or more substituents selected from the group consisting of oxo and —N(R5)2, wherein each R5 is independently selected from hydrogen and C1-C4 alkyl;
any heterocyclyl portion of R3 comprises at least one nitrogen atom in a ring, and is optionally substituted with one or more substituents selected from the group consisting of C1-C4 alkyl and oxo; and
any heteroaryl portion of R3 comprises at least one nitrogen atom in a ring and is optionally substituted with one or more C1-C4 alkyl.

### Claim 7 (depends on 6)

The method of claim 6, wherein R3 is —(C0-C1 alkylene)-heterocyclyl.

### Claim 8 (depends on 7)

The method of claim 7, wherein R3 is —(C1 alkylene)-heterocyclyl.

### Claim 9 (depends on 7)

The method of claim 7, wherein the heterocyclyl is selected from pyrazinyl, piperidinyl, morpholinyl, and pyrazolyl.

### Claim 10 (depends on 9)

The method of claim 9, wherein the heterocyclyl is morpholinyl.

### Claim 11 (depends on 1)

The method of claim 1, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R3 is optionally and independently substituted with one or more substituents selected from the group consisting of —OH, —SH, nitro, halogen, amino, cyano, C1-C12 alkyl, C2-C12 alkenyl or C2-C12 alkynyl group, C1-C12 alkoxy, C1-C12 haloalkyl, C1-C12 haloalkoxy and C1-C12 alkyl sulfanyl.

### Claim 12 (depends on 1)

The method of claim 1, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R3 is optionally and independently substituted with an amino group having the formula —N(R5)2, wherein each R5 is independently selected from hydrogen and C1-C4 alkyl.

### Claim 13 (depends on 1)

The method of claim 1, wherein:
any heteroaryl portion of R3 is optionally and independently substituted with one or more substituents selected from the group consisting of —OH, —SH, nitro, halogen, amino, cyano, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C1-C12 alkoxy, C1-C12 haloalkyl, C1-C12 haloalkoxy and C1-C12 alkyl sulfanyl; and
any alkyl, alkylene or heterocyclyl portion of R3 is optionally and independently substituted with one or more substituents selected from the group consisting of oxo, —OH, —SH, nitro, halogen, amino, cyano, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C1-C12 alkoxy, C1-C12 haloalkyl, C1-C12 haloalkoxy and C1-C12 alkyl sulfanyl.

### Claim 14 (depends on 1)

The method of claim 1, wherein
R3 is selected from —N(R4)—(C3-C6 cycloalkyl), —C3-C6 alkyl, —(C0-C1 alkylene)-heterocyclyl, and —(C0-C1 alkylene)-heteroaryl, wherein:
any alkyl or alkylene portion of R3 is optionally substituted with —N(R5)2, wherein
each R5 is independently selected from hydrogen and C1-C4 alkyl;
any heterocyclyl, and heteroaryl portion of R3 comprises at least one nitrogen atom in a ring; and
any heterocyclyl, and heteroaryl portion of R3 is optionally substituted with C1-C4 alkyl.

### Claim 15 (depends on 14)

The method of claim 14, wherein R3 is selected from —C(CH3)3, —CH(NH2)—CH(CH3)2, —NH-cyclopropyl, —(CH2)0-1-pyrazinyl, piperidinyl, hydroxypiperidinyl, N-methylpiperidinyl, —CH2-morpholin-4-yl, and methylpyrazolyl.

### Claim 16 (depends on 15)

The method of claim 15, wherein R3 is selected from —C(CH3)3, —CH(NH2)—CH(CH3)2, —NH-cyclopropyl, —(CH2)0-1-pyrazin-2-yl, piperidin-3-yl, —CH2-morpholin-4-yl, and 5-methyl-1-H-pyrazol-4-yl.

### Claim 17 (depends on 16)

The method of claim 16, wherein R3 is selected from —C(CH3)3, —NH-cyclopropyl, —CH2-pyrazin-2-yl, -pyrazin-2-yl, —CH2-morpholin-4-yl, and 5-methyl-1-H-pyrazol-4-yl.

### Claim 18 (depends on 1)

The method of claim 1, wherein the compound is represented by any one of the structural formulas set forth below:
Cmpd
No.
Compound Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
or a pharmaceutically acceptable salt thereof.

### Claim at position 19

19-31. (canceled)

### Claim 32 (depends on 8)

The method of claim 8, wherein the heterocyclyl is selected from pyrazinyl, piperidinyl, morpholinyl, and pyrazolyl.
